Tamoxifen for women at high risk of breast cancer
Safia A Nazarali, Steven A Narod Women's College Research Institute, Women's College Hospital, and The University of Toronto, Toronto, Ontario, Canada Abstract: Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and...
Enregistré dans:
Auteurs principaux: | Nazarali SA, Narod SA |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4f6dcb6d642a44e9ab0b890e2ff41d2a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
par: Katherine D. Crew, et autres
Publié: (2017) -
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
par: Sanne Løkkegaard, et autres
Publié: (2021) -
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
par: Andrea DeCensi, et autres
Publié: (2021) -
Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
par: Areepium N, et autres
Publié: (2013) -
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
par: Vogel VG
Publié: (2011)